pyrroles has been researched along with Eczema, Atopic in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (2.78) | 29.6817 |
| 2010's | 20 (55.56) | 24.3611 |
| 2020's | 15 (41.67) | 2.80 |
| Authors | Studies |
|---|---|
| Fujiyama, T; Honda, T; Kurihara, K; Tokura, Y | 1 |
| Ho, J; Molin, S | 1 |
| Agner, T; Bauer, A; Ehst, B; Korn, S; Resen, K; Schliemann, S; Shi, VY; Thyssen, JP; Tillmann, S; Worm, M | 1 |
| Chen, J; Cheng, J; Luo, X; Tu, W; Wang, H; Yang, H; Zhang, Y | 1 |
| Hide, M; Kamegashira, A; Morioke, S; Murakami, E; Numata, T; Saito, R; Suehiro, M; Takahagi, S; Takahashi, M; Tanaka, A | 1 |
| Chen, BZ; Guo, XD; Li, Z; Yang, Y; Zhang, CY; Zhang, XP; Zheng, H | 1 |
| Igarashi, A; Kabashima, K; Nagata, T; Nakagawa, H; Nemoto, O; Oda, M; Saeki, H | 2 |
| Igarashi, A; Kaino, H; Murata, R; Nagata, T; Nakagawa, H; Nemoto, O; Saeki, H | 1 |
| Amano, W; Egawa, G; Hamada, Y; Hayashi, M; Honda, T; Ishida, Y; Kabashima, K; Konishi, N; Matsushita, M; Nakashima, C; Otsuka, A; Tanimoto, A; Usui, K; Wada, M; Yamamoto, Y | 1 |
| Igarashi, A; Kaino, H; Nagata, T; Nakagawa, H; Nemoto, O; Saeki, H | 1 |
| Damsky, W; King, B; Peterson, D | 1 |
| Adachi, T; Doi, S; Hara, Y; Hase, Y; Hashimoto, H; Hori, A; Inoue, M; Kimoto, Y; Maeda, K; Miura, T; Negoro, T; Noji, S; Obika, S; Ogawa, Y; Oki, C; Orita, T; Shiozaki, M; Tanimoto, A; Yamamoto, H; Yamanaka, H | 1 |
| Kadono, T; Kishi, A; Mitsuishi, S; Miyagaki, T; Miyano, K; Nakajima, K; Okano, T; Takeuchi, S | 1 |
| Gong, Y; Qi, F; Zhang, J; Zhou, S; Zhu, B | 1 |
| Dainichi, T; Izumi, M; Kaku, Y; Kataoka, K | 1 |
| Amano, W; Hayashi, M; Kakimoto, K; Katsuda, Y; Kimoto, Y; Konishi, N; Shinozaki, Y; Taniai-Riya, E; Tanimoto, A; Toyoda, K; Yamamoto, Y | 1 |
| Igarashi, A; Nagata, T; Nakagawa, H; Nemoto, O | 1 |
| Heyes, C; Robertson, SJ; Ross, G; Varigos, GA; Vu, M | 1 |
| Lacour, JP | 1 |
| Bissonnette, R | 1 |
| Banovic, F; Blubaugh, A; Denley, T; Eguiluz-Hernandez, S; Elder, D; Rissi, D | 1 |
| Nagata, T; Nakagawa, H; Nemoto, O; Ninomiya, N; Yamada, H | 1 |
| Bäumer, W; Ehling, S; Fukuyama, T; Wilzopolski, J | 1 |
| Baron, J; Clarysse, K; Gutermuth, J; Huth, L; Kluwig, D; Kortekaas Krohn, I; Lüscher, B; Marquardt, Y; Pfaff, CM | 1 |
| Ports, WC; Purohit, VS; Riley, S; Wang, C | 1 |
| Sato, S; Suga, H | 1 |
| Fraser, K | 1 |
| Bäumer, W; Fukuyama, T; Qi, Y; Tschernig, T; Volmer, DA | 1 |
| King, BA; Levy, LL; Urban, J | 1 |
| Bissonnette, R; Gooderham, M; Mallbris, L; Mamolo, C; Papacharalambous, J; Papp, KA; Ports, WC; Poulin, Y; Purohit, V; Raman, M; Wang, C | 1 |
| Ahmad Nasrollahi, S; Firooz, A; Hashemi, A; Nassiri Kashani, M; Samadi, A | 1 |
| Ceovic, R; Gulin, SJ; Kostovic, K; Mokos, ZB | 1 |
| Damsky, W; King, BA | 1 |
| Hajheydari, Z; Mahmoudi, M; Moosa-Kazemi, SH; Nikookar, SH; Shahmohammadi, S | 1 |
| Hiraoka, M; Ito, S; Mayumi, M; Noiri, E; Ohta, N; Sato, S; Shibata, R; Tsukahara, H | 1 |
7 review(s) available for pyrroles and Eczema, Atopic
| Article | Year |
|---|---|
Delgocitinib in atopic dermatitis.
Topics: Child, Preschool; Dermatitis, Atopic; Humans; Janus Kinase Inhibitors; Pyrroles; Quality of Life | 2021 |
The efficacy and safety of Janus kinase inhibitors in patients with atopic dermatitis: A systematic review and meta-analysis.
Topics: Dermatitis, Atopic; Humans; Janus Kinase 1; Janus Kinase Inhibitors; Pyrroles; Treatment Outcome | 2022 |
Biological Therapies for Atopic Dermatitis: A Systematic Review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azetidines; Biological Products; Carbamates; Clinical Trials as Topic; Dermatitis, Atopic; Dermatologic Agents; Heterocyclic Compounds, 3-Ring; Humans; Nitriles; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides | 2021 |
Novel topical and systemic therapies in atopic dermatitis.
Topics: Acrylamides; Administration, Topical; Antibodies, Monoclonal, Humanized; Biological Products; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Dermatitis, Atopic; Humans; Immunotherapy; Interleukin-13; Janus Kinase Inhibitors; Molecular Targeted Therapy; Phosphodiesterase 4 Inhibitors; Piperidines; Pyridines; Pyrimidines; Pyrroles; Resorcinols; Stilbenes; TRPV Cation Channels | 2019 |
Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.
Topics: Alopecia Areata; Azetidines; Dermatitis, Atopic; Humans; Janus Kinase Inhibitors; Janus Kinases; Nitriles; Piperidines; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Skin Diseases; Sulfonamides; Vitiligo | 2017 |
Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology.
Topics: Administration, Oral; Alopecia Areata; Dermatitis, Atopic; Humans; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Signal Transduction; Skin Diseases; Vitiligo | 2017 |
JAK inhibitors in dermatology: The promise of a new drug class.
Topics: Alopecia Areata; Anti-Inflammatory Agents; Azetidines; Clinical Trials as Topic; Dermatitis, Atopic; Dermatologic Agents; Humans; Janus Kinases; Molecular Targeted Therapy; Nitriles; Piperidines; Protein Kinase Inhibitors; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Signal Transduction; Skin Diseases; Sulfonamides; Vitiligo | 2017 |
10 trial(s) available for pyrroles and Eczema, Atopic
| Article | Year |
|---|---|
The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial.
Topics: Adult; Dermatitis, Atopic; Double-Blind Method; Eczema; Emollients; Humans; Immunoglobulin A; Janus Kinase Inhibitors; Pain; Pruritus; Pyrroles; Severity of Illness Index; Treatment Outcome | 2022 |
Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis.
Topics: Adolescent; Child; Child, Preschool; Dermatitis, Atopic; Double-Blind Method; Female; Humans; Male; Ointments; Pyrroles | 2019 |
Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis.
Topics: Acne Vulgaris; Adolescent; Adult; Dermatitis, Atopic; Dermatitis, Contact; Drug Administration Schedule; Female; Folliculitis; Humans; Incidence; Janus Kinase Inhibitors; Japan; Male; Nasopharyngitis; Ointments; Pyrroles; Severity of Illness Index; Time Factors; Treatment Outcome; Young Adult | 2020 |
Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study.
Topics: Adult; Dermatitis, Atopic; Dermatologic Agents; Double-Blind Method; Female; Humans; Janus Kinase Inhibitors; Male; Ointments; Pyrroles; Treatment Outcome; Young Adult | 2020 |
Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study.
Topics: Adult; Child; Dermatitis, Atopic; Double-Blind Method; Eczema; Emollients; Humans; Ointments; Pyrroles; Treatment Outcome | 2021 |
Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Dermatitis, Atopic; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Ointments; Pruritus; Pyrroles; Treatment Outcome; Young Adult | 2018 |
Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis.
Topics: Administration, Cutaneous; Adult; Dermatitis, Atopic; Dermatitis, Phototoxic; Female; Healthy Volunteers; Humans; Janus Kinase Inhibitors; Japan; Male; Middle Aged; Ointments; Patch Tests; Placebos; Pruritus; Pyrroles; Severity of Illness Index; Skin; Treatment Outcome; Young Adult | 2018 |
Systemic Tofacitinib Concentrations in Adult Patients With Atopic Dermatitis Treated With 2% Tofacitinib Ointment and Application to Pediatric Study Planning.
Topics: Adult; Dermatitis, Atopic; Double-Blind Method; Humans; Models, Biological; Ointments; Pediatrics; Piperidines; Pyrimidines; Pyrroles | 2019 |
Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial.
Topics: Adolescent; Adult; Dermatitis, Atopic; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Ointments; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome; Young Adult | 2016 |
Comparison of topical triamcinolone and oral atorvastatin in treatment of paederus dermatitis Northern Iran.
Topics: Administration, Oral; Administration, Topical; Adolescent; Adult; Animals; Atorvastatin; Child; Coleoptera; Dermatitis, Atopic; Double-Blind Method; Female; Heptanoic Acids; Humans; Iran; Middle Aged; Placebos; Pyrroles; Treatment Outcome; Triamcinolone; Young Adult | 2012 |
19 other study(ies) available for pyrroles and Eczema, Atopic
| Article | Year |
|---|---|
Two cases of psoriasiform dermatitis arising during dupilumab therapy and successfully treated with delgocitinib ointment.
Topics: Administration, Topical; Adult; Antibodies, Monoclonal, Humanized; Dermatitis, Atopic; Dermatologic Agents; Drug Eruptions; Humans; Interleukin-4 Receptor alpha Subunit; Male; Ointments; Pyrroles; Treatment Outcome; Young Adult | 2021 |
Real-world efficacy of proactive maintenance treatment with delgocitinib ointment twice weekly in adult patients with atopic dermatitis.
Topics: Adult; Dermatitis, Atopic; Dermatologic Agents; Emollients; Glucocorticoids; Humans; Ointments; Pyrroles; Treatment Outcome | 2022 |
Conductive Microneedle Patch with Electricity-Triggered Drug Release Performance for Atopic Dermatitis Treatment.
Topics: Dermatitis, Atopic; Drug Delivery Systems; Electricity; Humans; Microinjections; Needles; Pharmaceutical Preparations; Platinum; Polyesters; Polymers; Pyrroles; Skin | 2022 |
Janus kinase inhibitor delgocitinib suppresses pruritus and nerve elongation in an atopic dermatitis murine model.
Topics: Administration, Cutaneous; Animals; Antipruritics; Dermatitis, Atopic; Disease Models, Animal; Female; Humans; Janus Kinase Inhibitors; Male; Mice; Pruritus; Pyrroles; Skin | 2020 |
The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Topics: Arthritis, Rheumatoid; Azetidines; Betacoronavirus; Colitis, Ulcerative; Coronavirus Infections; COVID-19; Cytokines; Dermatitis, Atopic; Heterocyclic Compounds, 3-Ring; Humans; Immunomodulation; Janus Kinases; Nitriles; Pandemics; Piperidines; Pneumonia, Viral; Primary Myelofibrosis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; SARS-CoV-2; STAT Transcription Factors; Sulfonamides | 2020 |
Discovery of a Janus Kinase Inhibitor Bearing a Highly Three-Dimensional Spiro Scaffold: JTE-052 (Delgocitinib) as a New Dermatological Agent to Treat Inflammatory Skin Disorders.
Topics: Dermatitis, Atopic; Dermatologic Agents; Drug Design; Humans; Inhibitory Concentration 50; Janus Kinase Inhibitors; Janus Kinases; Models, Molecular; Protein Conformation; Pyrroles | 2020 |
A case of facial redness in atopic dermatitis occurring during dupilumab treatment successfully treated with topical delgocitinib ointment.
Topics: Antibodies, Monoclonal, Humanized; Dermatitis, Atopic; Humans; Ointments; Pyrroles; Treatment Outcome | 2021 |
Successful treatment of severe blepharitis in a patient with atopic dermatitis by topical delgocitinib.
Topics: Administration, Topical; Blepharitis; Dermatitis, Atopic; Dermatologic Agents; Humans; Janus Kinase 1; Male; Pyrroles; Treatment Outcome; Young Adult | 2021 |
A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: Comparison with conventional therapeutic agents.
Topics: Animals; Cyclosporine; Cytokines; Dermatitis, Atopic; Female; Haptens; Humans; Immunoglobulin E; Inflammation; Interleukin-23; Interleukin-23 Subunit p19; Janus Kinase Inhibitors; Male; Methotrexate; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pyrroles; Rats; Rats, Inbred BN; Skin; Thymic Stromal Lymphopoietin | 2018 |
Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo.
Topics: Adult; Alopecia Areata; Dermatitis, Atopic; Humans; Janus Kinase Inhibitors; Male; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Th2 Cells; Treatment Outcome; Vitiligo | 2017 |
[Current and upcoming treatments of adult atopic dermatitis].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Glucocorticoids; Humans; Methotrexate; Mycophenolic Acid; Piperidines; Pyrimidines; Pyrroles; Thalidomide; Ustekinumab | 2017 |
JAK inhibitors appear to have a bright future in the treatment of atopic dermatitis.
Topics: Adult; Dermatitis, Atopic; Eczema; Humans; Janus Kinase Inhibitors; Pyrroles | 2018 |
The anti-inflammatory effect of topical tofacitinib on immediate and late-phase cutaneous allergic reactions in dogs: a placebo-controlled pilot study.
Topics: Animals; Anti-Inflammatory Agents; Dermatitis, Atopic; Dog Diseases; Dogs; Hypersensitivity, Delayed; Hypersensitivity, Immediate; Inflammation; Pilot Projects; Piperidines; Pyrimidines; Pyrroles | 2018 |
Comparison of topical tofacitinib and 0.1% hypochlorous acid in a murine atopic dermatitis model.
Topics: Administration, Topical; Animals; Cells, Cultured; Cytokines; Dermatitis, Atopic; Disease Models, Animal; Female; Ganglia, Spinal; Hypochlorous Acid; Immunoglobulin E; Mice; Neurons; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Skin | 2018 |
JAK1/3 inhibition preserves epidermal morphology in full-thickness 3D skin models of atopic dermatitis and psoriasis.
Topics: Cell Proliferation; Computer Simulation; Dermatitis, Atopic; Filaggrin Proteins; Humans; Imaging, Three-Dimensional; Intermediate Filament Proteins; Janus Kinase 1; Keratinocytes; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Sensitivity and Specificity; STAT6 Transcription Factor | 2019 |
72nd annual meeting of the American Academy of Dermatology.
Topics: Antifungal Agents; Attention Deficit Disorder with Hyperactivity; Boron Compounds; Botulinum Toxins, Type A; Bridged Bicyclo Compounds, Heterocyclic; Brimonidine Tartrate; Depression; Dermatitis, Atopic; Food Hypersensitivity; Humans; Immunologic Factors; Ivermectin; Phosphodiesterase Inhibitors; Phototherapy; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinoxalines; Skin Diseases; Societies, Medical; Thalidomide; Triazoles; United States | 2014 |
Aggression behaviour induced by oral administration of the Janus-kinase inhibitor tofacitinib, but not oclacitinib, under stressful conditions.
Topics: Administration, Oral; Aggression; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents; Behavior, Animal; Brain; Dermatitis, Atopic; Disease Models, Animal; Female; Janus Kinases; Male; Mice, Inbred BALB C; Piperidines; Protein Kinase Inhibitors; Pruritus; Pyrimidines; Pyrroles; Stress, Psychological; Sulfonamides; Toluene 2,4-Diisocyanate | 2015 |
Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate.
Topics: Administration, Oral; Adolescent; Adult; Dermatitis, Atopic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Janus Kinases; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Risk Assessment; Sampling Studies; Severity of Illness Index; Treatment Outcome; Young Adult | 2015 |
High levels of urinary pentosidine, an advanced glycation end product, in children with acute exacerbation of atopic dermatitis: relationship with oxidative stress.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Acute Disease; Arginine; Child; Child, Preschool; Creatinine; Deoxyguanosine; Dermatitis, Atopic; Female; Glycation End Products, Advanced; Humans; Lysine; Male; Norleucine; Oxidative Stress; Pyrroles | 2003 |